Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis.

ABSTRACT:

Background & aims

Cirrhosis poses a significant healthcare burden, with decompensation and acute-on-chronic liver failure (ACLF) resulting in high morbidity and mortality. Reliable biomarkers of disease progression are urgently needed. Urokinase plasminogen activator receptor (uPAR) and its soluble form (suPAR) are linked to systemic inflammation in liver disease. This study aims to evaluate suPAR as a prognostic marker and its role in chronic liver disease.

Methods

SuPAR levels were measured in a derivation cohort (n = 178) and a validation cohort (n = 197) from two centers, including healthy controls and patients with cirrhosis, acute decompensation, and ACLF. In a mouse model using carbon tetrachloride and lipopolysaccharide, suPAR levels correlated with liver uPAR expres

SUBMITTER: Lamatsch S 

PROVIDER: S-EPMC12907094 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature